Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Merkel Cell Carcinoma.

Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Soft Tissue Sarcoma.

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

The early administration probably maintained the sterility of the subdiaphragmatic and intrapleural fluid collection. Similarly, control of the intragastric infection prevented the development of ...

The influence of the mechanical work of breathing has a major impact on beat-by-beat and breath-by-breath right heart haemodynamics. With each inspiration, the small (2–5 cm H 2 0) change in ...

It arises as a result of the development of a one-way valve system at the site of the breach in the pleural membrane, permitting air to enter the pleural cavity during inspiration but preventing ...

Strategies include decreasing the following indicators to decrease the airflow across the BPF: peak inspiratory pressure, tidal volumes, positive end-expiratory pressure, inspiratory time, respiratory ...